HRS 4642
Alternative Names: HRS-4642Latest Information Update: 03 Nov 2026
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class 2 ring heterocyclic compounds; Antineoplastics; Azabicyclo compounds; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Naphthols; Oxazepines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Pancreatic cancer
- Phase II Adenocarcinoma
- Phase I/II Solid tumours
Most Recent Events
- 30 Oct 2026 Shanghai Hengrui Pharmaceutical plans a phase I pharmacokinetics trial for Pancreatic cancer (In volunteers) in China (IV) (NCT07906691)
- 28 Oct 2026 Shanghai Hengrui Pharmaceutical plans a phase III trial for Pancreatic cancer (First line therapy, Combination therapy) in China (Injection) (NCT07900789)
- 26 Oct 2026 The Third Xiangya Hospital of Central South University plans a phase I pharmacokinetic trial in Healthy adult volunteer in October 2026 (IV, Infusion) (NCT07894679)